Literature DB >> 11019780

Transforming growth factor-alpha and epidermal growth factor receptor in colonic mucosa in active and inactive inflammatory bowel disease.

K Hormi1, G Cadiot, S Kermorgant, V Dessirier, M Le Romancer, M J Lewin, M Mignon, T Lehy.   

Abstract

Transforming growth factor-alpha (TGF-alpha) is overexpressed in colonic carcinomas and promotes mucosal wound healing. It may be implicated in chronic inflammatory bowel disease (IBD). We analyzed the expression of TGF-alpha and its receptor, epidermal growth factor receptor (EGF-r), in the colonic mucosa of patients with Crohn's disease (CD) or ulcerative colitis (UC), in active or inactive stages, as compared with controls. Proteins and mRNA were detected in biopsies from the right and left colon and in surgical colonic specimens. Immunoblot analysis revealed TGF-alpha protein as a 29 kDa band. This band was normally expressed in uninvolved colonic mucosa of patients with CD or UC whether in active or inactive stages, but decreased or absent in involved mucosa of active IBD, even when TGF-alpha mRNA and EGF-r protein were detected. In the unaffected mucosa of CD, the intensity of TGF-alpha immunoreactivity was similar to that of controls in the right colon but stronger (P = 0.05) in the left colon. There was no TGF-alpha overexpression in dysplastic regions. In conclusion, in active IBD disease, the decreased TGF-alpha protein amount seems not only related to epithelial cell loss but reflects a down-regulation at least at the protein level. We speculate that TGF-alpha does not play a role within the active stage but may be implicated later in the repair process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11019780     DOI: 10.3109/08977190009003235

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  9 in total

1.  Additional prognostic factors in right colon cancer staging.

Authors:  Domenico Parmeggiani; Nicola Avenia; Adelmo Gubitosi; Francesco Gilio; Pietro Francesco Atelli; Massimo Agresti
Journal:  Updates Surg       Date:  2011-06-23

Review 2.  Current research in perineural invasion of cholangiocarcinoma.

Authors:  Fang-Zhen Shen; Bing-Yuan Zhang; Yu-Jie Feng; Zhuo-Xia Jia; Bing An; Chang-Chang Liu; Xi-Yun Deng; Anil D Kulkarni; Yun Lu
Journal:  J Exp Clin Cancer Res       Date:  2010-03-10

3.  Epidermal growth factor suppresses intestinal epithelial cell shedding through a MAPK-dependent pathway.

Authors:  Jennifer C Miguel; Adrienne A Maxwell; Jonathan J Hsieh; Lukas C Harnisch; Denise Al Alam; D Brent Polk; Ching-Ling Lien; Alastair J M Watson; Mark R Frey
Journal:  J Cell Sci       Date:  2016-03-29       Impact factor: 5.285

4.  Local delivery of growth factors using coated suture material.

Authors:  T F Fuchs; C Surke; R Stange; S Quandte; B Wildemann; M J Raschke; G Schmidmaier
Journal:  ScientificWorldJournal       Date:  2012-05-15

Review 5.  ErbB receptors and their growth factor ligands in pediatric intestinal inflammation.

Authors:  Mark R Frey; D Brent Polk
Journal:  Pediatr Res       Date:  2013-11-06       Impact factor: 3.756

Review 6.  NOD-like receptors in intestinal homeostasis and epithelial tissue repair.

Authors:  Marianna Parlato; Garabet Yeretssian
Journal:  Int J Mol Sci       Date:  2014-05-30       Impact factor: 5.923

7.  ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation.

Authors:  Michael A Schumacher; Matija Hedl; Clara Abraham; Jessica K Bernard; Patricia R Lozano; Jonathan J Hsieh; Dana Almohazey; Edie B Bucar; Shivesh Punit; Peter J Dempsey; Mark R Frey
Journal:  Cell Death Dis       Date:  2017-02-23       Impact factor: 8.469

8.  Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles.

Authors:  Erik Andersson; Daniel Bergemalm; Robert Kruse; Gunter Neumann; Mauro D'Amato; Dirk Repsilber; Jonas Halfvarson
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

9.  Pharmacological activation of epidermal growth factor receptor signaling inhibits colitis-associated cancer in mice.

Authors:  Philip E Dubé; Cambrian Y Liu; Nandini Girish; M Kay Washington; D Brent Polk
Journal:  Sci Rep       Date:  2018-06-14       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.